We assessed changes in hemodynamic and arterial stiffness parameters following reductions of dialysate calcium concentrations in patients undergoing hemodialysis. Methods: In this prospective study, 20 patients on maintenance hemodialysis (10 females, 10 males) with dialysate calcium concentrations of 1.75 mmol/L were enrolled. At the start of the study, the dialysate calcium level was lowered to 1.50 mmol/L. Serial changes in biochemical, hemodynamic, and arterial stiffness parameters, including pulse wave velocity (PWV) and augmentation index (AIx), were assessed every 2 months for 6 months. We also examined changes in the calcification-inhibitory protein, serum fetuin-A. Results: During the 6-month study period, serum total calcium and ionized calcium decreased consistently (9.5 ± 1.0 to 9.0 ± 0.7, p = 0.002 vs. 1.3 ± 0.1 to 1.1 ± 0.1, p = 0.035). Although no apparent changes in blood pressure were observed, heart-femoral PWW (hf-PWV) and AIx showed significant improvement (p = 0.012, 0.043, respectively). Repeatedmeasures ANOVA indicated a significant effect of lowering dialysate calcium on hf-PWV (F = 4.58, p = 0.004) and AIx (F = 2.55, p = 0.049). Accompanying the change in serum calcium, serum fetuin-A levels significantly increased (95.8 ± 45.8 pmol/mL at baseline to 124.9 ± 82.2 pmol/mL at 6 months, p = 0.043). Conclusions: Lowering dialysate calcium concentration significantly improved arterial stiffness parameters, which may have been associated with upregulation of serum fetuin-A.
depends on the gradient between serum and dialysate calcium concentrations [7] [8] [9] , understanding the effects of lowering dialysate calcium concentrations in patients undergoing hemodialysis is important. To date, several studies have examined the complex relationships among serum calcium levels, the degree of vascular calcification, and arterial stiffness in patients with ESRD, and low calcium dialysate has been reported to reduce serum calcium levels, which is helpful in improving arterial stiffness [10, 11] . However, these studies were relatively short-term trials and did not demonstrate serial changes in arterial stiffness. Moreover, no reported study has evaluated the relationship between serum calcium concentrations and changes in serum fetuin-A, a calcification-inhibitory protein.
In this study, we prospectively evaluated changes in hemodynamic and arterial stiffness parameters, including pulse wave velocity (PWV) and augmentation index (AIx), after lowering dialysate calcium concentrations for 6 months in patients on hemodialysis. Changes in serum fetuin-A levels were also examined.
MetHoDS
This was a single-center, prospective observational study performed at Gangnam Severance Hospital in Seoul, Biochemical and hemodynamic data were obtained at baseline. Total calcium, ionized calcium, phosphorus, serum creatinine, albumin, intact parathyroid hormone (PTH), and C-reactive protein levels were checked under standardized fasting conditions immediately before the start of dialysis sessions. Using an automatic blood pressure monitor device, blood pressure was measured in the resting state before (pre-dialysis) and after (post-dialysis) each session. The mean value of three consecutive measurements was used. Arterial stiffness parameters (PWV, AIx) were measured after dialysis in the resting state.
After the baseline measurement, the dialysate calcium concentration was lowered, from 1.75 to 1.5 mmol/L, and this change was maintained for 6 months. Blood samples were taken and arterial stiffness parameters were checked every 2 months. In total, four blood tests and arterial stiffness measurements were taken during the 6 months (T 0 , T 2month , T 4month , and T 6month ).
Blood samples were also obtained for assessment of serum fetuin-A levels. Serum fetuin-A levels were checked twice, at baseline and at the end of the study (T 0 and T 6month ). To assess serum fetuin-A, the collected blood samples were immediately centrifuged (5,000 g, 10 minutes) and then stored at -70°C until the assays were performed.
A commercially available enzyme-linked immunosorbent assay (ELISA) kit (DuoSet ELISA Development kit, R&D Systems, Minneapolis, MN, USA) was used. Intra-and inter-assay coefficients of variation were less than 10%. In each subject, two sequences of measurements were performed and their mean value was used for the statistical analysis.
To assess additional calcium sources, a complete medication list, including calcium-containing phosphate binders and vitamin D agents, was reviewed. Adverse events, including hypotension and muscle cramps, were surveyed during the study period.
Assessment of arterial stiffness parameters
PWV and AIx were assessed using an automated device 
Data analysis
Statistical analyses were performed using the SPSS ver- 
ReSuLtS

Baseline characteristics
In total, 20 maintenance hemodialysis patients participated in this study. The baseline clinical characteristics of the patients are outlined in Table 1 
Changes in clinical and biochemical parameters during 6 months
The effects of reducing dialysate calcium on clinical and biochemical parameters are listed in Table 2 . No significant change occurred in body weight, ultrafiltration rate, or adverse event rate during hemodialysis. After lowering dialysate calcium, serum total calcium levels decreased significantly, from 9.5 ± 1.0 mg/dL at baseline to 9.0 ± 0.7 mg/dL at 6 months (p = 0.031), and serum ionized calcium levels also decreased, from 1.3 ± 0.1 mmol/L to 1.1 ± 0.1 mmol/L (p = 0.001). Serum phosphorus levels increased significantly (4.8 ± 1.2 at baseline vs. 5.6 ± 1.5 at 6 months; p = 0.025), and serum intact PTH levels increased gradually, from 80.6 ± 51.7 pg/mL at baseline to a maximum of 253.8 ± 160.9 pg/mL at 4 months (p < 0.001). At this point, active vitamin D treatment was administered to five patients to prevent secondary hyperparathyroidism and the intact PTH level decreased thereafter to 137.0 ± 79.4 pg/mL at 6 months; however, the difference was still significant (p = 0.001). No significant change was observed in hemoglobin, calcium-phosphorus product, glucose, uric acid, total cholesterol, or C-reactive protein levels over the study period.
Changes in hemodynamic and arterial stiffness parameters and fetuin-A
No apparent change was detected in systolic, diastolic, mean arterial blood pressure, or pulse pressure during follow-up (Table 3) . However, hf-PWV and heart rate-adjusted AIx showed significant improvements (1,548 ± 450 cm/sec, 23.3 ± 17.5%, at baseline vs. 1,288 ± 345 cm/sec, 15.2 ± 19.0% at 6 months; p = 0.012, 0.043, respectively).
Moreover, accompanying the changes in serum calcium levels, serum fetuin-A levels increased significantly, from 95.8 ± 45.8 pmol/mL at baseline to 124.9 ± 82.2 pmol/ mL at 6 months (p = 0.043; Fig 1) . A negative and significant correlation was detected between serum calcium and fetuin-A level (r = -0.52, p = 0.027 at 6 months).
Reduction in serum calcium and its relationship with arterial stiffness markers
The percentage change in serum calcium level (∆serum calcium, %) was significantly correlated with the change in post-dialysis hf-PWV (∆hf-PWV, r = 0.721, p < 0.001) and the serum fetuin-A level (∆fetuin-A; r = -0.463, p = 0.046; Fig. 2 ). Further analysis, using repeated-measures ANOVA, confirmed the significant effect of lowering dialysate calcium on hf-PWV (F = 4.58, p = 0.004) and heart rate-adjusted AIx (F = 2.55, p = 0.049).
DISCuSSIon
Arterial stiffness is an important manifestation of vascular calcification. Although vascular calcification is thought to result from old age and atherosclerosis, not all vascular calcification occurs in the presence of atherosclerosis. Previously, physicochemical factors alone, such as calcium-phosphate derangement and alkaline pH, were thought to regulate the development of vascular calcification. However, recent studies have demonstrated that it is an elaborately regulated process, involving bone morphogenic proteins including osteoprotegerin and fetuin-A, and metabolic disorders such as uremia [12] [13] [14] [15] .
Because serum calcium levels depend on the diffusion rate between the dialysate and serum calcium concentration gradient, special attention is paid to the dialysate calcium level [7, 8] . PWV, and they suggested that even an acute decrease in serum calcium levels from reduced dialysate calcium can lead to a detectable improvement in central PWV. A longer study was conducted by Demirci et al. [3] with patients on peritoneal dialysis. They used higher dialysate calcium over 6 months and found a significant worsening of brachial PWV, but the change was not detected with low dialysate calcium treatment. These results are similar to our data, except that we assessed central PWV, not brachial ankle PWV. Although ba-PWV is used as a convenient and accurate method to assess central arterial stiffness [10] , unlike hf-PWV, ba-PWV includes peripheral stiffness with the measurements of peripheral artery velocity [17] . Generally, the correlation between central and peripheral PWV is not definite, suggesting that arterial stiffening does not occur equally, especially in patients with renal dysfunction. In fact, the increase in PWV is most significant in the hf (central) segment compared with the femoral-ankle (peripheral) segment in these patients. Similarly in patients with ischemic heart disease (IHD), the positive association between IHD and PWV was significant only in the hf segment, when an adjustment was made for other confounding factors [18] . We thought that because of the relatively short duration of our study, only a change in hf-PWV was observed. However, with longer term follow-up, we think that improvement in ba-PWV would also occur.
Several previous studies reported that the serum phosphate level decreased with reduced dialysate calcium concentrations [19, 20] . In contrast to previous studies, the serum phosphate level in our patients actually increased, from a pretreatment value of 4.8 ± 1.2 to 5.6 ± 1.5 mg/dL at 6 months after the treatment (p < 0.05). This finding may be explained by changes in the phosphate binder. Initially, approximately 30% of patients (6/20) used non-calciumbased phosphate binders, such as sevelamer hydrochloride or lanthanum carbonate, which have stronger phosphatebinding capacity without hypercalcemia. However, as serum calcium levels decreased, many of our patients changed phosphate binders, to equivalent doses of the calcium-based phosphate binder, calcium acetate (PhosLo; each dose of sevelamer 800 mg or lanthanum 500 mg was changed to calcium acetate 667 mg). Although the dose of the calcium-based phosphate binder was similar to that of the non-calcium-based phosphate binder, serum phosphate levels in our patient group seemed to rise, probably due to the lower efficacy of the calcium-based phosphate binder. Additionally, five patients received active vitamin D treatment after 4 months, which may also have contributed to the increased serum phosphate level. With those five patients, the baseline serum phosphate level was 4.98 ± 1.41 mg/dL, but the level increased to 5.59 ± 1.60 and 5.76 ± 1.75 mg/dL at 4 and 6 months, respectively. AIx improvements in our study were independent of blood pressure may suggest that the decrease in serum calcium concentrations affects arterial stiffness by a mechanism other than blood pressure control.
Another finding in this study is the significant rise in the serum fetuin-A level accompanying the improvement in central PWV. Fetuin-A, an abundant serum protein produced in the liver, forms calcioprotein particles and thereby prevents aggregation of calcium phosphate into insoluble mineral crystals [22] . It is also expressed in bone, accumulates at sites of vascular calcification, and plays a role in skeletal mineralization, possibly through the inhibition of calcification [5, 23] . In in vitro studies, fetuin-A contributes about 50% of the calcification-inhibitory capacity of human plasma [22] . Recently, several studies have reported a protective role of fetuin-A against arterial stiffness and cardiovascular mortality in patients with ESRD; our results are consistent with these findings [24] [25] [26] [27] .
A cohort study of 258 patients with ESRD starting renal replacement therapy showed that a low fetuin-A level was associated with increased cardiovascular and all-cause mortality [25] . Shroff et al. [24] also reported that fetuin-A level increased in patients on dialysis compared to healthy controls, and that fetuin-A levels were negatively correlated with dialysis duration, PWV, and vascular calcification.
In our study, after reducing the level of dialysate calcium, serum fetuin-A levels increased significantly and correlation analysis showed a negative association between percentage change of serum calcium and fetuin-A levels during the whole study period, suggesting a possible role of fetuin-A in improving arterial stiffness via upregulation. Although our study could not show a significant direct correlation between fetuin-A level and PWV or AIx, this may have been due to the small sample size. Our study had several limitations. The generalizability of our findings may be limited because our sample size was relatively small and we did not include a control group, which may have reduced statistical power. However, to minimize the confounding factors, we fixed the medication list, such as antihypertensive and lipid-lowering agents, and controlled dry weight to maintain euvolemic status. Although vitamin D treatment in five patients may have been a confounding factor, vitamin D analogs were used after 4 months in all patients. Thus, improvements in PWV and AIx at 2 and 4 months were most likely due to reduced dialysate calcium concentrations, and was not a vitamin D effect. However, a randomized controlled trial with more subjects is necessary, and further long-term follow-up is needed to establish the long-term effects of lowering the dialysate calcium concentration.
In conclusion, lowering the dialysate calcium concentration induced a blood pressure-independent, favorable effect in arterial stiffness parameters, as indicated by improved AIx and central PWV. These findings may be associated with the upregulation of serum fetuin-A.
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